Oslo, Norway, 6 July 2016:
Photocure ASA will present its second quarter report on Tuesday 23
August 2016 at Hotel Continental, Norway, and is proud to announce
Dr. Sia Daneshmand as keynote speaker at the event. Dr. Daneshmand
will provide an update on Hexvix/Cysview following the new bladder
cancer guidelines from American Urological Association (AUA) and
the Society of Urological Oncology (SUO), where enhanced cystoscopy
including Blue Light Cystoscopy with Hexvix/ Cysview is
recommended.
Agenda (CET)
08:30 -
09:05 Q2
presentation by Kjetil Hestdal, President and CEO, and Erik Dahl,
CFO
09:05 -
09:15
Break
09:15 -
09:45 Dr. Sia
Daneshmand, MD, Associate Professor of Urology (Clinical Scholar);
Director of Urologic Oncology, Director of Research and Fellowship
Director, USC Institute of Urology at University of Southern
California, Los Angeles, USA
09:45 -
10:00 Ambaw
Bellete, President, Photocure Inc. and Head, US Commercial
Operations
A light snack will be served from 08:00.
The presentations will be live streamed at
www.photocure.com. More details will be provided later.
To attend the presentation, please register by
sending an email to gfs@photocure.no.
For further information, please
contact:
Photocure
Erik Dahl, CFO
Tel: +47 450 55 000, Email: ed@photocure.com
Notes to
editors
About Photocure
ASA
Photocure, headquartered in Oslo
Norway, is a specialty pharmaceutical company and world leader in
photodynamic technology. Based on our unique proprietary Photocure
Technology(TM) platform, Photocure develops and commercializes
highly selective and effective solutions within disease areas with
high unmet medical need, such as bladder cancer, HPV and
precancerous cervical lesions, colorectal cancer and skin
conditions. Our aim is to provide solutions which can improve
health outcomes for patients worldwide. Photocure is listed on the
Oslo Stock Exchange (OSE: PHO). Information about Photocure is
available at www.photocure.com
This information is subject to the
disclosure requirements pursuant to section 5-12 of the Norwegian
Securities Trading Act.
